In this study, cepharanthine and tetrandrine demonstrated efficacy against SARS-CoV-2 in a cell-based infection assay, with cepharanthine showing a lower IC50 value.
7 citations
,
March 2023 in “Arabian Journal of Chemistry” This study suggests that cepharanthine may play an important role in treating SARS-CoV-2 infection by targeting multiple pathways and related targets associated with COVID-19.
8 citations
,
July 2023 in “Frontiers in Pharmacology” This review highlights cepharanthine as a promising candidate for COVID-19 treatment due to its antiviral activity against SARS-CoV-2 and favorable pharmacokinetic and safety profile, but reports no new clinical results.
3 citations
,
June 2023 in “Molecules/Molecules online/Molecules annual” The researchers reviewed cepharanthine, a long-used bisbenzylisoquinoline alkaloid, for its antiviral properties, including significant inhibition of SARS-CoV-2. They discussed cepharanthine's other pharmacological actions, highlighted plasma membrane fluidity as a key antiviral mechanism, and examined its safety, bioavailability, and potential for new clinical applications.
This review examines cepharanthine's antiviral potential against COVID-19 and finds no clinical results yet; it highlights cepharanthine as a potent inhibitor of coronavirus in preclinical models.
